The present invention relates to GFRAL antagonist antibodies and uses thereof, and more specifically, to anti-GFRAL antibodies comprising heavy chain CDR and light chain CDR of specific sequences, and antigen-binding fragments thereof. Anti-GFRAL antibodies are expected to be useful in the alleviation or treatment of cancer-related anorexia-cachexia syndrome, as well as adverse reactions caused by chemotherapeutics.
